Payment overview · 2025
General Payments
$146.33
7 reported records · 7 companies
Healthcare provider profile · identity verified
James Darrel King, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · SELMER, TN · NPI 1144256157
Verified facts
What the public records show
CMS Open Payments records show James Darrel King, M.D. received $146.33 in general payments during 2025 across 7 reported records.
Abbott Laboratories accounted for 18.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rexulti, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $26.34 | 18.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $24.61 | 16.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $23.05 | 15.8% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $19.28 | 13.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.83 | 12.9% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $18.10 | 12.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.12 | 11.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $146.33 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $24.61 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $23.05 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $19.28 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $18.83 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $18.10 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.12 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
77 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Furosemide | Furosemide | 1226 | 82 |
| Eliquis | Apixaban | 1209 | 60 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1117 | 61 |
| Atorvastatin Calcium | Atorvastatin Calcium | 972 | 79 |
| Potassium Chloride | Potassium Chloride | 876 | 56 |
| Clopidogrel | Clopidogrel Bisulfate | 865 | 41 |
| Escitalopram Oxalate | Escitalopram Oxalate | 827 | 48 |
| Sertraline Hcl | Sertraline Hcl | 814 | 34 |
| Buspirone Hcl | Buspirone Hcl | 775 | 45 |
| Pantoprazole Sodium | Pantoprazole Sodium | 730 | 45 |
| Omeprazole | Omeprazole | 711 | 56 |
| Carvedilol | Carvedilol | 701 | 35 |
| Losartan Potassium | Losartan Potassium | 680 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 658 | 44 |
| Amlodipine Besylate | Amlodipine Besylate | 653 | 50 |
| Lisinopril | Lisinopril | 599 | 36 |
| Divalproex Sodium | Divalproex Sodium | 554 | 28 |
| Mirtazapine | Mirtazapine | 550 | 42 |
| Donepezil Hcl | Donepezil Hcl | 528 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 497 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 479 | 33 |
| Metoprolol Succinate | Metoprolol Succinate | 470 | 29 |
| Famotidine | Famotidine | 464 | 21 |
| Gabapentin | Gabapentin | 441 | 65 |
| Levetiracetam | Levetiracetam | 434 | 23 |
| Trazodone Hcl | Trazodone Hcl | 350 | 32 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 344 | 21 |
| Olanzapine | Olanzapine | 343 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 340 | 25 |
| Metformin Hcl | Metformin Hcl | 338 | 27 |
| Hydralazine Hcl | Hydralazine Hcl | 325 | 24 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 303 | 19 |
| Risperidone | Risperidone | 283 | 16 |
| Propranolol Hcl | Propranolol Hcl | 257 | suppressed |
| Memantine Hcl | Memantine Hcl | 244 | 14 |
| Diltiazem 24hr Er | Diltiazem Hcl | 242 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 235 | 17 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 224 | 41 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 214 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 193 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 193 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 187 | 17 |
| Baclofen | Baclofen | 179 | suppressed |
| Simvastatin | Simvastatin | 175 | 14 |
| Spironolactone | Spironolactone | 173 | 17 |
| Rivastigmine | Rivastigmine Tartrate | 169 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 165 | 13 |
| Allopurinol | Allopurinol | 157 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 136 | 15 |
| Oxcarbazepine | Oxcarbazepine | 136 | suppressed |
| Jardiance | Empagliflozin | 132 | suppressed |
| Lovastatin | Lovastatin | 129 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 116 | 21 |
| Digoxin | Digoxin | 113 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 108 | suppressed |
| Rivastigmine | Rivastigmine | 108 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 106 | suppressed |
| Lorazepam | Lorazepam | 104 | 25 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 102 | suppressed |
| Haloperidol | Haloperidol | 102 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 97 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 96 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 95 | suppressed |
| Alprazolam | Alprazolam | 92 | 17 |
| Montelukast Sodium | Montelukast Sodium | 92 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 92 | 11 |
| Divalproex Sodium Er | Divalproex Sodium | 91 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 90 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 88 | suppressed |
| Prednisone | Prednisone | 88 | 22 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 84 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 84 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 80 | suppressed |
| Brilinta | Ticagrelor | 77 | suppressed |
| Lamotrigine | Lamotrigine | 77 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 75 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 74 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 73 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 69 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 68 | 26 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 66 | 19 |
| Pregabalin | Pregabalin | 66 | 11 |
| Ondansetron Odt | Ondansetron | 65 | suppressed |
| Finasteride | Finasteride | 64 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 63 | suppressed |
| Aripiprazole | Aripiprazole | 62 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 62 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 62 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 60 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 60 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 60 | 22 |
| Januvia | Sitagliptin Phosphate | 58 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 58 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 57 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 57 | suppressed |
| Topiramate | Topiramate | 57 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 55 | suppressed |
| Sotalol | Sotalol Hcl | 55 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 54 | 19 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 53 | 16 |
| Roflumilast | Roflumilast | 53 | suppressed |
| Dutasteride | Dutasteride | 51 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 51 | suppressed |
| Nystatin | Nystatin | 51 | 30 |
| Carbamazepine Er | Carbamazepine | 50 | suppressed |
| Xarelto | Rivaroxaban | 50 | suppressed |
| Nifedipine Er | Nifedipine | 49 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 48 | suppressed |
| Amantadine | Amantadine Hcl | 47 | suppressed |
| Entresto | Sacubitril/Valsartan | 47 | suppressed |
| Budesonide | Budesonide | 46 | suppressed |
| Perphenazine | Perphenazine | 46 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 45 | suppressed |
| Cilostazol | Cilostazol | 44 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 44 | suppressed |
| Fluconazole | Fluconazole | 43 | 24 |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 43 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 43 | suppressed |
| Minoxidil | Minoxidil | 43 | suppressed |
| Rexulti | Brexpiprazole | 43 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 42 | suppressed |
| Lidocaine | Lidocaine | 42 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 42 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 41 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 41 | suppressed |
| Trulicity | Dulaglutide | 40 | suppressed |
| Glimepiride | Glimepiride | 38 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 38 | 15 |
| Metolazone | Metolazone | 38 | suppressed |
| Nystop | Nystatin | 38 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 37 | 22 |
| Calcitriol | Calcitriol | 37 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 36 | suppressed |
| Matzim La | Diltiazem Hcl | 36 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 36 | suppressed |
| Cephalexin | Cephalexin | 35 | 27 |
| Ibuprofen | Ibuprofen | 35 | suppressed |
| Latanoprost | Latanoprost | 35 | suppressed |
| Zonisamide | Zonisamide | 35 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 33 | suppressed |
| Lactulose | Lactulose | 33 | suppressed |
| Valsartan | Valsartan | 33 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 32 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 31 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 31 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 31 | suppressed |
| Ramelteon | Ramelteon | 31 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 31 | suppressed |
| Levemir | Insulin Detemir | 29 | suppressed |
| Novolog | Insulin Aspart | 29 | suppressed |
| Acebutolol Hcl | Acebutolol Hcl | 28 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 28 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 28 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 26 | suppressed |
| Linzess | Linaclotide | 26 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 26 | suppressed |
| Ramipril | Ramipril | 26 | suppressed |
| Lacosamide | Lacosamide | 25 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 25 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 25 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 24 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 21 |
| Dicyclomine Hcl | Dicyclomine Hcl | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Levofloxacin | Levofloxacin | 22 | 16 |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 22 | suppressed |
| Cimetidine | Cimetidine | 21 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 21 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 20 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 20 | suppressed |
| Levemir Flexpen | Insulin Detemir | 20 | suppressed |
| Calcium Acetate | Calcium Acetate | 19 | suppressed |
| Carbamazepine | Carbamazepine | 19 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 19 | suppressed |
| Verquvo | Vericiguat | 19 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 18 | 12 |
| Combigan | Brimonidine Tartrate/Timolol | 18 | suppressed |
| Gemfibrozil | Gemfibrozil | 18 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 18 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | suppressed |
| Bumetanide | Bumetanide | 17 | suppressed |
| Fentanyl | Fentanyl | 17 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 17 | suppressed |
| Meloxicam | Meloxicam | 17 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 17 | suppressed |
| Ranolazine Er | Ranolazine | 17 | suppressed |
| Serevent Diskus | Salmeterol Xinafoate | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | 16 |
| Clozapine | Clozapine | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | suppressed |
| Novolin R | Insulin Regular, Human | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 14 |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 14 | 12 |
| Dexamethasone | Dexamethasone | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Valproic Acid | Valproic Acid | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 12 |
| Clonazepam | Clonazepam | 13 | suppressed |
| Ezetimibe | Ezetimibe | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Trimethoprim | Trimethoprim | 13 | suppressed |
| Unifine Safecontrol Pen Needle | Pen Needle,dual Safety,diabetc | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 12 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Azathioprine | Azathioprine | 11 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Daptomycin | Daptomycin | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Ozempic | Semaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $146.33 · 7 records | Abbott Laboratories | BREZTRI, Cologuard Collection Kit, NUPLAZID, Ozempic, REXULTI, TRELEGY ELLIPTA | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error